Ascendis Pharma Inc. - ASND Quarterly EPS earnings growth
Ascendis Pharma A/S (ASND) relies on TransCon technology for rare endocrine pathologies. The company's growth trajectory depends on the approval of new licenses in Europe and the US. Meanwhile, high R&D expenditures are putting pressure on operating income. The intensity of quarterly EPS growth reflects market expectations, and this metric stood at 581.10.
%20Quarterly%20EPS%20earnings%20growth&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_ASND_-_Ascendis-Pharma-AS_-_Quarterly-EPS-earnings-growth "ASND ascendispharma.com Quarterly EPS earnings growth (07/04/2022 - 11/12/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Ascendis (ASND)
- share price and consensus valuation forecast:
- issuer market value details:
- balance sheet net asset value indicators:
- debt and liquidity data:
Debt to Equity Ascendis Pharma A/S|ASND - Long-Term Debt to Equity|Short-Term Debt to Capital Ascendis Pharma A/S|ASND - Company Total Debt Obligations|Debt to Book Capitalization Ratio Ascendis Pharma Inc.|ASND - Long-Term Debt Volume|Company Short-Term Debt Ascendis Pharma|Quick Ratio ascendispharma.com
- earnings and valuation multiples indicators:
ASND - Net Profit|Expected Profit Ascendis Pharma A/S|ASND - Business Payback Period|Forward P/E Multiple Ascendis Pharma Inc.|ASND - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Ascendis Pharma Inc.|ASND - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Ascendis Pharma|ASND - Earnings per share for the last 12 months|Quarterly EPS earnings growth ascendispharma.com|ASND - Earnings per share growth this year|Earnings growth forecast for next year Ascendis Pharma A/S
Analysis of all company metrics:Ascendis Pharma A/S
Monopoly pricing for TransCon orphan drugs provides Ascendis Pharma A/S (ASND) with high margins and financial stability. This factor directly determines the growth rate of earnings per share, measuring the increase in net income for the current quarter relative to the same period last year. The metric captures the real operational efficiency of the business between reporting periods. Analyzing quarterly earnings per share trends allows for the timely detection of a slowdown in expansion. A downward trend on the chart signals the risk of overpaying for the asset.
Competitors of Ascendis Pharma A/S (ASND)
MDGL (Madrigal Pharmaceuticals, Inc.) - Year-over-year net earnings per share growth for the last 12 months|CORT: Year-over-year earnings per share growth rate for the last twelve months|RYTM (Rhythm Pharmaceuticals Inc) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Akero Corp|Quarterly EPS earnings growth MTSR|Year-over-year earnings per share growth for the last twelve months MLTX (moonlaketx.com)|Year-over-year earnings per share growth for the last twelve months Crinetics CRNX|NewAmsterdam Pharma Company (NAMS) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Therapeutics Inc.|MiMedx Group Inc (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rezolute Corp (RZLT)|Year-over-year net earnings per share growth for the last 12 months Lexicon Corp LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences Inc)|Quarterly EPS earnings growth altimmune.com ALT|AARD - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Sagimet Biosciences, Inc. SGMT|BIOA: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Biomea Fusion Corp|QNCX (Quince Therapeutics Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months fractyl.com GUTS|Year-over-year earnings per share growth for the last twelve months vTv Therapeutics Inc. (VTVT)|agapeatpgroup.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth PLUR (Pluri)|SYBX: Year-over-year earnings per share growth for the last 12 months|Lipocine Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma MTNB|Spruce Biosciences (SPRB) - Year-over-year earnings per share growth for the last twelve months|GLTO - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months CTCX|LUMO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Organovo Holdings, Inc. (ONVO)|RDUS: Year-over-year net earnings per share trend for the last twelve months
